| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H32O3 |
| Molecular Weight | 356.4984 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]3([H])C4=C(CC[C@@]23[H])C=C(OC5CCCC5)C=C4
InChI
InChIKey=ODYKCPYPRCJXLY-PZORDLPLSA-N
InChI=1S/C23H32O3/c1-23-11-10-18-17-9-7-16(26-15-4-2-3-5-15)12-14(17)6-8-19(18)20(23)13-21(24)22(23)25/h7,9,12,15,18-22,24-25H,2-6,8,10-11,13H2,1H3/t18-,19-,20+,21-,22+,23+/m1/s1
| Molecular Formula | C23H32O3 |
| Molecular Weight | 356.4984 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Quinestradol is an estrogen derivative patented by Francesco Vismara Societa per Azioni and Alberto Ercol for the treatment of senile vulvovaginitis and related conditions. In preclinical trilals, quinestradol shows feminizing action in rats. A clinical trial of Quinestradol appeared to be justified since there was considerable evidence that the preparation was safe and free from side effects.
